Xencor Company Description
Don't come to Xencor if you need the hem adjusted on your new pants: The company tailors proteins, not pants. Xencor is developing therapeutics for cancer and autoimmune diseases. The company engineers antibodies using its Protein Design Automation (PDA) technology to more effectively treat disease. Its lead drug candidate targets rheumatoid arthritis, Crohn's disease, and psoriasis. Other disease targets Xencor is pursuing include thrombocytopenia (the death of blood platelets due to chemotherapy), multiple sclerosis and other autoimmune diseases, and osteoporosis. Research partners include Roche and Centocor; major investors include NovoNordisk and MedImmune.
View the Comprehensive Company Description for Xencor
The Company Description provides a historical perspective of Xencor's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Xencor's evolution in the marketplace.
